Onvansertib
NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with an IC50 of 2 nM.
Product Specifications
CAS Number
1034616-18-6
Product Name Alternative
NMS-1286937; NMS-P937
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Polo-like Kinase (PLK)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/NMS-1286937.html
Purity
99.86
Solubility
DMSO : 21 mg/mL (ultrasonic; warming)
Smiles
O=C(C1=NN(CCO)C2=C1CCC3=CN=C(NC4=CC(N5CCN(C)CC5)=CC=C4OC(F)(F)F)N=C23)N
Molecular Formula
C24H27F3N8O3
Molecular Weight
532.52
Precautions
H302, H315, H319, H335
References & Citations
[1]Beria I, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett. 2011 May 15;21 (10) :2969-74.|[2]Valsasina B, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11 (4) :1006-16.|[3]Casolaro A, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8 (3) :e58424.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PLK1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![Mouse Monoclonal Cytokeratin 14 Antibody (rKRT14/7290) [DyLight 405]](https://cdn.genprice.uk/genprice/uk/genprice2.webp)
NBP3-20972V 0.1 mL
Mouse Monoclonal Cytokeratin 14 Antibody (rKRT14/7290) [DyLight 405]
Sign In for Pricing
View Details 
K1264107 1.0 µg DNA
MAP3K10 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)
Sign In for Pricing
View Details 